Meta AnalysisID 7641
胆碱酯酶抑制剂与抗β-淀粉样蛋白单克隆抗体治疗轻中度阿尔茨海默病的有效性与安全性比较
CRD42023493904
How do cholinesterase inhibitors and anti-amyloid-β monoclonal antibodies compare in terms of effectiveness and safety for patients with mild to moderate Alzheimer's disease?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 7641
- Evidence Id
- 16199
- Core Evidence Id
- 16199
- Source Meta Analysis Id
- 7635
- Herb2 Meta Analysis Id
- HBMA007635
- Crd Id
- CRD42023493904
- Title
- Comparing Effectiveness and Safety of cholinesterase inhibitors vs anti-amyloid-β monoclonal antibodies in Patients with mild to moderate Alzheimer’s disease
- Review Question
- How do cholinesterase inhibitors and anti-amyloid-β monoclonal antibodies compare in terms of effectiveness and safety for patients with mild to moderate Alzheimer's disease?
- Study Type Included
- Randomized clinical trials will be included irrespective of blinding, publication status or language
- Condition Being Studied
- Study patients were diagnosed with mild to moderate Alzheimer’s disease
- Participant
- patients were diagnosed with mild to moderate Alzheimer’s disease
- Animal
- Human Disease Modelled
- Intervention
- Galantamine, rivastigmine, and donepezil, aducanumab, lecanemab, donanemab
- Comparator Control
- Placebo
- Main Outcome
- Outcomes of interest includes: 1. AD Assessment Scale–Cognitive Subscale (ADAS-Cog), Mini-Mental State Examination (MMSE) 2.Assessment of functional status using validated scales such as the Alzheimer's Disease Cooperative Study Activities of Daily Living Scale (ADCS-ADL) or the Clinical Dementia Rating Scale (CDR) 3.Adverse events will be documented based on participants' reports, medical records, and investigator assessments.
- Outcome Measure
- Additional Outcome
- Study Method
- Network meta-analysis, Systematic review
- Keyword
- MeSH headings have not been applied to this record
- Contact
- Yaqing Chen [email protected]
- Organisational Affiliation
- CRO
- Funding Source
- No
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2023-12-15
- Registration Date
- 2023-12-26
- Anticipated Start Date
- 2023-12-15
- Anticipated Completion Date
- 2024-03-15
- Title Cn
- 胆碱酯酶抑制剂与抗β-淀粉样蛋白单克隆抗体治疗轻中度阿尔茨海默病的有效性与安全性比较
- Title En
- Comparing Effectiveness and Safety of cholinesterase inhibitors vs anti-amyloid-β monoclonal antibodies in Patients with mild to moderate Alzheimer’s disease
- Bilingual Status
- complete